

Supplemental Table 1. Some Examples of Cell-based Immunotherapy Strategies (DC) for Glioma

Cells used	Year published	Adult/Childhood gliomas	First author	Affiliated as	ref
DC cells	2020	adult	Jeremy D. Rudnick	Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States	1
autologous dendritic cell vaccine	2018	adult	Linda M. Liau	University of California Los Angeles (UCLA) David Geffen School of Medicine & Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA	2
Dendritic cell-based immunotherapy targeting Wilms' tumor 1	2015	adult	Keiichi Sakai	Department of Neurosurgery, National Hospital Organization, Shinshu Ueda Medical Center, Ueda, Nagano, Japan	3
Intraventricular B7-H3 CAR T Cells	2023	Childhood (DIPG*)	Nicholas A. Vitanza	Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.	4
IL13R $\alpha$ 2 CAR T cell	2016	Adult	Christine E. Brown	Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory, City of Hope Beckman Research Institute and Medical Center, Duarte, CA	5
Autologous CMV-specific T cells	2020	Adult	Corey Smith	QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumor Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 2 NEWRO Foundation, Brisbane, Queensland, Australia	6
Autologous HER2 CMV bispecific CAR T cells	2015	Adult	Nabil Ahmed	Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA	7
EGFRvIII CAR T Cell	2021	Adult	Joseph S. Durgin	Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States	8
HER2-Specific CAR T cells	2017	Adult	Nabil Ahmed	Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston	9
EGFRvIII-directed CAR T cells	2017	Adult	DONALD M. O'ROURKE	Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.	10

\* DIPG: Diffuse Intrinsic Pontine Glioma

**References:**

1. Rudnick, Jeremy D., et al. "A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma." *Journal of Clinical Neuroscience* 74 (2020): 187-193.
2. Liao, Linda M., et al. "First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma." *Journal of translational medicine* 16.1 (2018): 1-9.
3. Sakai, Keiichi, et al. "Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma." *Journal of Neurosurgery* 123.4 (2015): 989-997.
4. Vitanza, Nicholas A., et al. "Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety." *Cancer discovery* 13.1 (2023): 114-131.
5. Brown, Christine E., et al. "Regression of glioblastoma after chimeric antigen receptor T-cell therapy." *New England Journal of Medicine* 375.26 (2016): 2561-2569.
6. Smith, Corey, et al. "Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme." *The Journal of clinical investigation* 130.11 (2020): 6041-6053.
7. Ahmed, Nabil, et al. "Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial." *Journal for immunotherapy of cancer* 3 (2015): 1-1.
8. Durgin, Joseph S., et al. "Case report: prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma." *Frontiers in Oncology* 11 (2021): 669071.
9. Ahmed, Nabil, et al. "HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial." *JAMA oncology* 3.8 (2017): 1094-1101.
10. O'Rourke, Donald M., et al. "A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma." *Science translational medicine* 9.399 (2017): eaaa0984.